According to the Zhitong Finance App, Conoa-B (02162) announced that the company expects to make a profit of not less than RMB 1.2 billion in the first half of 2026, while the loss for the same period last year was approximately RMB 79 million.
According to the announcement, the main reason for turning a loss into profit was: ① Previously sold the Group's minority shares in Ouro Medicines, and the Group received a total down payment equivalent to US$257 million in the second quarter of 2026. This down payment was confirmed as other income during the reporting period, which was approximately RMB 1.68 billion. ② KYM Biosciences Inc. (KYM, a 70% non-wholly-owned subsidiary of the Group) entered into a license agreement with AstraZeneca for CMG901 (Claudin 18.2 ADC). In the first quarter of 2026, AstraZeneca announced that it had initiated a multi-center, randomized controlled, phase III clinical study (Clarity 02) with or without CMG901 (AZD0901) combined with capecitabine or Rilvegostomig for first-line treatment of claudin18.2-positive and HER2-negative advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma, and completed the first patient administration, triggering related milestone payments. The Group has received milestone payments totaling US$31.5 million in the first quarter of 2026. This milestone payment has been recognized as cooperative revenue during the reporting period, which is approximately RMB 220 million. ③ The company's innovative product Kangyueda® has outstanding clinical value, and the number of patients covered continues to increase. The first half of 2026 achieved sales revenue of 390 million yuan, an increase of 132% over the previous year, providing the company with continuous revenue.
Since January 1, 2026, Kangyueda® has been approved for marketing in adults for the three indications of severe atopic dermatitis (AD), chronic rhinosinusitis with nasal polyps (CRSwnP), and seasonal allergic rhinitis (SAR), as well as the packaging of the Xillin bottle and prefilled autoinjector pen, have been included in China National Medicine In the list of insured drugs, the medical insurance payment standard is RMB 1,039 per bottle (specification is 300mg/2ml), which greatly enhances affordability and accessibility for Chinese patients. As of June 30, 2026, the company's commercialization team has reached more than 500 people, covering more than 1,600 hospitals and more than 260 cities, and the market entry process is progressing rapidly.
In addition, in January and March 2026, marketing applications for spiximab for moderate to severe AD and Prurigo Nodularis (PN) in adolescents were accepted by the China National Drug Administration respectively.
Kangyueda®'s strong performance in the first half of 2026 validated its market potential, further strengthened the company's confidence in commercialization, and brought stable cash flow to the company. At the same time, the company continues to promote global innovation, and multiple BD progress verification platforms have innovative potential and diversified licensing cooperation results, opening up room for continuous growth in corporate value. The company and partners are rapidly advancing multiple clinical studies in the pipeline of CMG901 (Claudin18.2 ADC), CM336 (BCMA/CD3 double antibody), and CM512 (TSLP × IL13 dual antibody), and are continuing to increase early innovation in central nervous system (CNS) and other fields.
The group continues to optimize scientific and efficient cost management capabilities, and while accelerating the development of innovative products and pipeline promotion, it has also achieved results in cost control.